DK1351709T3 - Pegylering af linkere forbedrer antitumorvirkning og reducerer immunkonjugaters tokcitet - Google Patents

Pegylering af linkere forbedrer antitumorvirkning og reducerer immunkonjugaters tokcitet

Info

Publication number
DK1351709T3
DK1351709T3 DK01948294T DK01948294T DK1351709T3 DK 1351709 T3 DK1351709 T3 DK 1351709T3 DK 01948294 T DK01948294 T DK 01948294T DK 01948294 T DK01948294 T DK 01948294T DK 1351709 T3 DK1351709 T3 DK 1351709T3
Authority
DK
Denmark
Prior art keywords
pegylation
antitumor activity
toxicity
reduces
present
Prior art date
Application number
DK01948294T
Other languages
English (en)
Inventor
Ira H Pastan
Byungkook Lee
Robert J Kreitman
Yasuo Tsutsumi
Masanori Onda
Satoshi Nagata
Original Assignee
Us Gov Health & Human Serv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv filed Critical Us Gov Health & Human Serv
Application granted granted Critical
Publication of DK1351709T3 publication Critical patent/DK1351709T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6829—Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Polyethers (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK01948294T 2000-06-09 2001-06-08 Pegylering af linkere forbedrer antitumorvirkning og reducerer immunkonjugaters tokcitet DK1351709T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21133100P 2000-06-09 2000-06-09
US21380400P 2000-06-22 2000-06-22
PCT/US2001/018503 WO2001095942A2 (en) 2000-06-09 2001-06-08 Pegylation of linkers improves antitumor activity and reduces toxicity of immunoconjugates

Publications (1)

Publication Number Publication Date
DK1351709T3 true DK1351709T3 (da) 2005-01-31

Family

ID=26906053

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01948294T DK1351709T3 (da) 2000-06-09 2001-06-08 Pegylering af linkere forbedrer antitumorvirkning og reducerer immunkonjugaters tokcitet

Country Status (9)

Country Link
EP (1) EP1351709B8 (da)
JP (1) JP2004503512A (da)
AT (1) ATE275979T1 (da)
AU (2) AU6976201A (da)
CA (1) CA2411967A1 (da)
DE (1) DE60105647T2 (da)
DK (1) DK1351709T3 (da)
ES (1) ES2228903T3 (da)
WO (1) WO2001095942A2 (da)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7229841B2 (en) 2001-04-30 2007-06-12 Cytimmune Sciences, Inc. Colloidal metal compositions and methods
AU2004220325B2 (en) * 2003-06-30 2011-05-12 Domantis Limited Polypeptides
EP1769000B1 (en) * 2004-07-16 2014-12-24 Amgen Research (Munich) GmbH Expression-enhanced polypeptides
US7935804B2 (en) 2006-03-01 2011-05-03 Aduro Biotech Engineered Listeria and methods of use thereof
WO2007103225A2 (en) 2006-03-01 2007-09-13 Anza Therapeutics, Inc. Engineered listeria and methods of use thereof
CN101835801B (zh) * 2007-08-08 2014-09-10 诺维信生物制药丹麦公司 转铁蛋白变体和偶联物
JP5485152B2 (ja) * 2007-08-15 2014-05-07 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 単一特異性および多特異性抗体ならびに使用方法
US7800951B2 (en) 2007-08-20 2010-09-21 Marvell World Trade Ltd. Threshold voltage digitizer for array of programmable threshold transistors
RS54057B1 (en) 2010-12-03 2015-10-30 Adamed Sp. Zo.O. ANTIKANCERSKI PROTEIN FUNCTIONS
WO2014029012A1 (en) * 2012-08-23 2014-02-27 Stemcell Technologies Inc. Compositions and methods for rapid and reversible biomolecular labeling
WO2022178751A1 (en) * 2021-02-25 2022-09-01 Shanghai Allygen Biologics Co., Ltd. Targeting conjugates comprising effector molecules and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1810832B (zh) * 1998-10-23 2012-12-12 麒麟-安姆根有限公司 与MPl受体结合并具有血小板生成活性的模拟二聚体血小板生成素肽

Also Published As

Publication number Publication date
AU2001269762B2 (en) 2005-06-23
AU2001269762C1 (en) 2005-12-22
ES2228903T3 (es) 2005-04-16
DE60105647D1 (de) 2004-10-21
ATE275979T1 (de) 2004-10-15
EP1351709B8 (en) 2004-12-22
CA2411967A1 (en) 2001-12-20
WO2001095942A2 (en) 2001-12-20
DE60105647T2 (de) 2005-09-22
EP1351709B1 (en) 2004-09-15
WO2001095942A3 (en) 2003-07-31
JP2004503512A (ja) 2004-02-05
EP1351709A2 (en) 2003-10-15
AU6976201A (en) 2001-12-24

Similar Documents

Publication Publication Date Title
MX2023013118A (es) Derivados del exatecan y sus conjugados anticuerpo-farmaco.
IL169045A (en) Immunoconjugates
DK1351709T3 (da) Pegylering af linkere forbedrer antitumorvirkning og reducerer immunkonjugaters tokcitet
EP1017397A4 (en) PHOTO SENSITIVITY-INCREASING CONJUGATE FOR TARGETING PATHOGENES
IL135148A0 (en) A polysaccharide conjugate and pharmaceutical compositions containing the same
DK1346731T3 (da) Konjugater til behandling af inflammatoriske forstyrrelser og tilsvarende vævsskade
WO2005112919A8 (en) Self-immolative linkers and drug conjugates
MXPA03011094A (es) Citotoxinas, profarmacos, ligadores, y estabilizadores utiles para ello.
MX2008002597A (es) Proceso para preparar conjugados de anticuerpo y maytansinoide.
BR122018071968B8 (pt) conjugado de anticorpo-droga, composição farmacêutica, artigo de manufatura e uso de um conjugado de anticorpo-droga
WO2003106659A3 (en) TOXIN-APTAMER MOLECULES AND METHODS OF USE THEREOF
MXPA05007851A (es) Conjugados de anticuerpos-antraciclina.
HK1244452A1 (zh) 用經不可切割接頭連接的細胞結合劑美登木素生物鹼偶聯物
WO2000064486A3 (en) Enzymatically activated polymeric drug conjugates
ATE451124T1 (de) Polysaccharid-peptid-konjugate
MX2009006410A (es) Conjugados de polimero-oligonucleotido, proteina y/o peptido.
NZ762865A (en) Psma-targeting amanitin conjugates
WO2018124512A3 (ko) 압타머-약물 콘쥬게이트 및 그 용도
AU2002215904A1 (en) Compounds with a branched linker
WO2007064661A3 (en) Bifunctional metal chelating conjugates
MX2022015147A (es) Conjugados de anticuerpos biespecíficos-fármacos dirigidos al receptor del factor de crecimiento epidérmico (egfr) y glicoproteína de transmembrana de tipo 1 (muc1) y usos de los mismos.
PT1107793E (pt) Conjugados de dextrano-leptina, composicoes farmaceuticas e processos relacionados
WO2005041881A8 (en) Taxoid-fatty acid conjugates and pharmaceutical compositions thereof
WO2002049672A3 (en) Conjugates of antibodies and anticancer drugs
HK1067492A1 (en) Method of making a homogenous doxorubicin-transferrin conjugate